Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO

Toxicology

Volumn 192, Issue 2-3, 2003, Pages 219-227

  Phillips, Anna ^a   Bullock, Tabitha ^a   Plant, Nick ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Apoptosis; Caspase 11; Hepatotoxicity; Sodium valproate

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 11; CASPASE 3; DNA FRAGMENT; FAS LIGAND; ISOENZYME; PROTEOME; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CHROMATIN CONDENSATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DRUG EXPOSURE; HEPATOMA CELL; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

APOGON BRACHYGRAMMUS;

EID: 0142154020     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(03)00331-7     Document Type: Article

References (29)

1. Bayly A.C.et al. Non-genotoxic hepatocarcingenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J. Cell Sci. 104:1993;307-315.
2. Bjorge S.M., Baillie T.A. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem. Biophys. Res. Commun. 132(1):1985;245-252.
3. Demeret C.et al. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene. 22(2):2003;168-175.
4. Earnshaw W.C.et al. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 68:1999;383-424.
5. Hengartner M.O. The biochemistry of apoptosis. Nature. 407(6805):2000;770-776.
6. Hoffmann A.et al. Transcriptional activities of the zinc finger protein zac are differentially controlled by DNA binding. Mol. Cell. Biol. 23(3):2003;988-1003.
7. Ichiyama T.et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 857(1-2):2000;246-251.
8. Jeavons P. Non-dose related side effects of valproate. Epilepsia. 25(S1):1984;S50-S55.
9. Kang S.J.et al. Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J. Cell Biol. 149.3:2000;613-622.
10. Kawagoe R.et al. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and caspase-independent apoptotic signaling pathways. Leuk. Res. 26(5):2002;495-502.
11. Kesterson J.W.et al. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology. 4(6):1984;1143-1152.
12. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58(1):1999;31-59.
13. Loscher W., Vetter M. In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Biochem. Pharmacol. 34:1985;1747-1756.
14. MacLachlan T.K., El-Deiry W.S. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc. Natl. Acad. Sci. U.S.A. 99(14):2002;9492- 9497.
15. Maher S.et al. Activation-induced cell death: the controversial role of Fas and Fas-ligand in immune privilege and tumour counterattack. Immunol. Cell. Biol. 80(2):2002;131-137.
16. McLaughlin D.B.et al. Apparent autoinduction of valproate β-oxidation in humans. Br. J. Clin. Pharmacol. 49(5):2000;409-415.
17. McLean M., Macdonald R. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237:1986;1001-1011.
18. Michaelson J.S., Leder P. RNAi reveals anti-apoptotic and transcriptionally repressive activities of Daxx. J. Cell Sci. 116(Pt 2):2003;345-352.
19. Noda H.et al. Increased proliferative activity caused by loss of p21(WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma. Cancer. 94(7):2002;2107-2112.
20. Penry J.K., Dean J.C. The scope and use of valproate in epilepsy. J. Clin. Psychiatry. 50:1989;17-22.
21. Plant N.et al. Differential gene expression in rats following subacute exposure to the anticonvulsant sodium valproate. Toxicol. Appl. Pharmacol. 183(2):2002;127-134.
22. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J. 7(5):1993;453-463.
23. Serrano B.B.et al. Valproate population pharmacokinetics in children. J. Clin. Pharmacol. Ther. 24(1):1999;73-80.
24. Tang W.et al. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases. Drug Metab. Dispos. 24(4):1996;436-446.
25. Wang S.et al. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell. 92(4):1998;501-509.
26. Wang J.-F.et al. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol. Pharmacol. 55:1999;521-527.
27. Wu S.et al. Ultraviolet radiation-induced apoptosis is mediated by Daxx. Neoplasia. 4(6):2002;486-492.
28. Zeise M.L.et al. Valproate suppresses N-methyl-D-asparate evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544:1991;345-348.
29. Zhou T.et al. Immunobiology of tumor necrosis factor receptor superfamily. Immunol. Res. 26(1-3):2002;323-336.